Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is the Phoenix definition superior to ASTRO for predicting clinical outcomes in prostate cancer?

Nature Clinical Practice Urology volume 5, pages 356–357 (2008)Cite this article

boxed-textAbramowitz et al. (2007) The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112: 55–60

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597

    Article  CAS  Google Scholar 

  2. Freedland SJ et al. (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176: 1404–1408

    Article  Google Scholar 

  3. Stephenson AJ et al. (2006) Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24: 3973–3978

    Article  CAS  Google Scholar 

  4. D'Amico AV et al. (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95: 1376–1383

    Article  Google Scholar 

  5. Pollack A et al. (2002) Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54: 677–685

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Nick Groves-Kirkby, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A100, Cleveland, OH 44195-0001, USA stephea2@ccf.org

Authors and Affiliations

  1. AJ Stephenson is an Assistant Professor of Urology at the Cleveland Clinic Lerner College of Medicine, and an Attending Staff member in urologic oncology at the Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.,

    Andrew J Stephenson

Authors
  1. Andrew J Stephenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stephenson, A. Is the Phoenix definition superior to ASTRO for predicting clinical outcomes in prostate cancer?. Nat Rev Urol 5, 356–357 (2008). https://doi.org/10.1038/ncpuro1126

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro1126

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing